DUBLIN, Calif., Aug. 17 SuperGen Inc.(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapiddevelopment and commercialization of therapies for solid tumors andhematological malignancies, today announced that Audrey F. Jakubowski, Ph.D.,Chief Regulatory and Quality Officer will retire effective today. Dr.Jakubowski's primary responsibilities have been transitioned to David S.Smith, Ph.D., who earlier this year joined SuperGen as Vice President,Regulatory and Quality Affairs.
"Dr. Jakubowski has been extremely instrumental in guiding and growingSuperGen's regulatory and quality efforts over the years," said Dr. JamesManuso, President and CEO. "A valued colleague, Audrey created and nurtured ahighly effective organization and approach to regulatory affairs and qualitymanagement that the Company will continue under Dr. David Smith's leadership."
Dr. Smith, 52, joined SuperGen in March 2007. Prior to joining SuperGen,Dr. Smith was Senior Director, Regulatory Strategy at Wyeth ConsumerHealthcare. His responsibilities included obtaining new product registrationson a global level, US marketed product support, and providing scientific andregulatory guidance to business development initiatives. From 1996 to 2000,Dr. Smith served as Regulatory Affairs Program Director at Roche Pharma. Dr.Smith began his regulatory career in 1987 at Schering-Plough, where he focusedon the development and registration of oncology and biotechnology products.During his tenure at Schering-Plough, he concentrated on European Unionactivities and major markets outside of the U.S. Dr. Smith's trainingincludes a post-doctoral fellowship and research in biochemical genetics atthe Roche Institute of Molecular Biology. He received a Ph.D. in pharmacologyfrom Wayne State University School of Medicine, and a B.S. in Biophysics, alsofrom Wayne State University.
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical companydedicated to the discovery, rapid development and commercialization oftherapies for solid tumors and hematological malignancies. SuperGen isdeveloping a number of therapeutic anticancer products focused on kinase andcell signaling inhibitors and DNA methyltransferase inhibitors. For moreinformation about SuperGen, please visit http://www.supergen.com.Contacts: Timothy L. Enns Mary M. Vegh SuperGen, Inc. SuperGen, Inc. SVP, Corporate Communications Manager, Investor Relations & Business Development Tel: (925) 560-2845 Tel: (925) 560-0100 E-mail: firstname.lastname@example.org E-mail: email@example.com
SOURCE SuperGen Inc.